ALTSTATION.IO

STERIS plc (STE) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$247.81

Change

+1.64%

Market Cap

$24.41B

Avg Volume

645.7K

Company Overview

STERIS plc is a global leader in infection prevention, offering a wide range of products and services tailored for the healthcare, life sciences, and applied sterilization markets. Their Healthcare segment provides essential cleaning chemicals, sterilizers, endoscopy accessories, and capital equipment critical for maintaining sterile processing departments and procedure rooms. Clients include hospitals, healthcare providers, and pharmaceutical manufacturers that rely on STERIS’s equipment management and maintenance services to ensure safety and compliance.

In terms of competitive positioning, STERIS is a market leader in the healthcare sterilization space, benefitting from a broad product portfolio and extensive service capabilities. They compete against firms like 3M and Getinge, leveraging strengths in innovation and a comprehensive range of integrated solutions. However, they face challenges from pricing pressures and the increasing demand for rapid sterilization solutions that may require adaptation and investment in new technologies.

Currently, STERIS is in a growth phase, significantly bolstered by its strategic focus on expanding its life sciences segment and enhancing its service offerings. Recent milestones include the expansion of their sterilization facilities and developments in automated systems, which are expected to drive revenue in the coming years. The company’s commitment to innovation and process improvement positions it well to capture new market opportunities and sustain its competitive edge.

Key Financials

Market Cap

$24.41B

Revenue

$5.83B

EBITDA

$1.56B

Gross Margin

44.3%

Profit Margin

12.1%

Revenue Growth

9.2%

Total Cash

$423.70M

Total Debt

$1.90B

Free Cash Flow

$892.16M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

34.56

Forward P/E

22.30

Beta

1.04

52-Week High

$269.44

52-Week Low

$204.90

EPS

$7.17

50-Day Avg

$259.07

200-Day Avg

$245.00

Price/Book

3.39

Technical Analysis

The overall trend for STERIS plc (STE) over the 52-week period indicates a moderate upward trajectory, with the stock currently priced at $247.81, reflecting a 13.3% increase. Key support levels are noted around $220, where price bounces frequently occurred, while resistance is found near $252.16, which marks recent highs. There have been notable price consolidation phases, particularly between August and September and again in November through January, where the stock oscillated within defined ranges. Recent momentum shows a slight decline from the peak near $252.16, as prices have retraced, potentially indicating a short-term correction. Presently, the current price sits comfortably above the 52-week low of around $210, implying relative strength, though it remains below the recent high, suggesting potential resistance in breaking through prior peaks. Overall, while the long-term trend is positive, recent activity hints at consolidation or corrective phases, necessitating close monitoring of price levels in the coming weeks.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for STERIS plc (STE) stock in the past week, covering February 1-7, 2026:

1. STERIS Reports Strong Q3 Fiscal 2026 Earnings

STERIS plc announced its third-quarter fiscal year 2026 earnings on February 5, 2026, after the market closed, with the earnings call held on the same day. The company reported adjusted earnings per diluted share of $2.53, marking a 9% increase compared to the prior year. Total as-reported revenue also saw a 9% growth, with constant currency organic revenue up 8%, while free cash flow significantly improved.

2. Analysts Maintain “Buy” Consensus with Positive Price Targets

Leading up to and following the earnings release, several analysts reiterated their positive outlook for STERIS plc. The stock currently holds a “Buy” or “Moderate Buy” consensus rating from analysts, with average price targets ranging from approximately $273.50 to $293.00. While some firms like Morgan Stanley and JPMorgan maintained “Equal Weight” or “Neutral” ratings on January 26, 2026, they did slightly increase their price targets for STE.

Market Sentiment and Analyst Recommendations

Bull Case

STERIS just delivered 9% earnings growth with adjusted EPS of $2.53, and organic revenue expanded 8% in constant currency. Free cash flow improved meaningfully, which matters more than top-line noise. The company trades at 34.56x P/E, which looks expensive until you realize they’re growing faster than the 9.2% headline suggests when you strip out currency headwinds. Eight analysts recommend buy with targets averaging $281.62, implying 13.6% upside from current levels. The healthcare sterilization and infection prevention market has structural tailwinds from aging populations and hospital capex cycles that won’t reverse. STERIS sits with $423.70M in cash against $1.90B debt, giving them room to fund growth or return capital. The dividend at $0.63 quarterly provides income while they execute, making this a compounder for patient investors.

Bear Case

At 34.56x P/E, you’re paying a premium for mid-single-digit growth, and the market has already priced in most good news. The stock retraced from $252.16 to $247.81 after earnings, suggesting momentum is fragile. Revenue growth of 9.2% is solid but not exceptional for a company trading at this multiple, especially if macro conditions tighten hospital spending. Debt sits at $1.90B against $5.83B revenue, which is manageable but limits financial flexibility in a downturn. Morgan Stanley and JPMorgan stayed neutral even after the earnings beat, signaling skepticism from major banks about near-term catalysts. The stock has consolidated multiple times between August and January, indicating institutional hesitation to chase higher. If the 52-week high at $269.44 becomes hard resistance again, you’re looking at limited upside from here.

What to Watch

Monitor free cash flow conversion over the next two quarters. If it continues improving, that validates the bull thesis and could push the stock through $252.16 resistance. Watch gross margins closely on the next earnings call in May. Any compression would signal pricing power is weakening or input costs are rising. Track the dividend sustainability. A $0.63 quarterly payment is about 1% yield, but if earnings growth stalls, management might pause increases, which would disappoint. Keep an eye on hospital capex spending data and elective procedure volumes. These drive STERIS’s core business, and any softening would justify the bear case. The stock needs to break and hold above $252.16 to signal a breakout from consolidation. If it rolls over below $240, the next major support is $220, and that would suggest a longer correction is underway. Finally, watch analyst commentary at the next earnings date for signs of demand weakness in their key end markets.

Analyst Consensus

BUY

Based on 8 analyst opinions

Low Target

$231.00

Mean Target

$281.62

High Target

$300.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

17,787

Earnings & Dividends

Next Earnings

Feb 04, 2026

EPS (Trailing)

$7.17

Dividend Yield

101.0%

Payout Ratio

33.5%

Frequently Asked Questions

Is STERIS plc (STE) a good stock to buy?

Yes, analysts recommend STERIS as a “BUY” with a target price of $281.62. The solid fundamentals and a P/E ratio of 34.56 suggest potential growth in a strong healthcare market.

What is STERIS’s price target?

The price target for STERIS plc is $281.62. This target indicates an upside potential of about 13.5% from the current price of $247.81.

Does STERIS pay a dividend?

Yes, STERIS has a dividend yield of 101.0%. This high yield makes it attractive for income-focused investors, although it’s advisable to check the sustainability of such a high yield.

What is STERIS’s market cap and how does it position the company?

STERIS has a market cap of $24.41 billion. This positions the company as a significant player in the medical device industry, signaling stability and investor confidence.

What is STERIS’s 52-week price range?

STERIS’s 52-week price range is $204.90 to $269.44. This range shows volatility, but also highlights a recovery trend since touching the lower end earlier in the year.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.